Indolent Lymphoma - Market Insight, Epidemiology, and Market Forecast - 2034

Key Highlights

• Non-Hodgkin Lymphoma (NHL) divided into major two prognostic groups: indolent lymphomas and aggressive lymphomas. Indolent lymphoma refers to a category of slow-progressing B-cell non-Hodgkin lymphomas that includes subtypes such as follicular lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma or chronic lymphocytic lymphoma.
• Indolent lymphoma accounts for 41% of all NHL cases in North America and Northern Europe.
• The treatment paradigm is rapidly shifting from traditional chemoimmunotherapy to more personalized and durable approaches like watchful waiting, new molecular targeted agents, and many more where the need for long-term disease control with minimal toxicity especially as many patients are diagnosed at an older age can live with the disease for decades.
• In August 2025, Bristol Myers Squibb announced US Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) for BREYANZI (lisocabtagene maraleucel) as a potential treatment for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least two prior lines of systemic therapy.
• In February 2025, Regeneron Pharmaceuticals announced that it has resubmitted the Biologics License Application (BLA) for odronextamab in relapsed/refractory follicular lymphoma to the FDA. The company anticipates a decision from the FDA by the second half of 2025.
• In December 2024, CRISPR Therapeutics announced that the US FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX112 for the treatment of R/R follicular lymphoma and marginal zone lymphoma.
• Currently treatment armamentarium includes the US FDA approved JAYPIRCA (pirtobrutinib), CALQUENCE (acalabrutinib), IMBRUVICA (Ibrutinib), BRUKINSA (zanubrutinib), EPKINLY (epcoritamab-bysp), ORDSPONO (odronextamab), KYMRIAH (tisagenlecleucel), YESCARTA (axicabtagene ciloleucel), BREYANZI (lisocabtagene maraleucel), and others.
• Several potential therapies are being investigated for the management of indolent lymphoma. The anticipated launch of the promising candidate like AZD0486, EO2463, Abexinostat, CTX112, Docirbrutinib, NVG-111, and others during the forecast period (2025-2034) is expected to bring about a significant shift in the market dynamics of indolent lymphoma.

The " Indolent Lymphoma - Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Indolent Lymphoma, historical and forecasted epidemiology as well as the Indolent Lymphoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The indolent lymphoma market report provides current treatment practices, emerging drugs, indolent lymphoma share of individual therapies, and current and forecasted indolent lymphoma market size from 2020 to 2034, segmented by seven major markets. The report also covers current indolent lymphoma treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Indolent Lymphoma Understanding and Treatment Algorithm

Indolent Lymphoma Overview

Indolent lymphoma is a slow-growing type of non-Hodgkin lymphoma that primarily affects B cells and often progresses over many years. Common subtypes include follicular lymphoma, marginal zone lymphoma, and small lymphocytic lymphoma (SLL)/chronic lymphocytic lymphoma (CLL). While some patients remain asymptomatic for a long time, typical signs and symptoms can include painless swollen lymph nodes, fatigue, night sweats, unexplained weight loss, and recurrent infections. The exact cause is unknown, but risk factors may include genetic mutations, immune system dysfunction, chronic infections, or exposure to certain chemicals or radiation. Due to its slow progression, indolent lymphoma is often monitored closely and treated only when symptoms worsen or disease activity increases.

Indolent Lymphoma Diagnosis

Indolent lymphoma is a slow-growing form of non-Hodgkin lymphoma that typically arises from B cells and progresses over years, often with minimal or no symptoms in the early stages. While the exact cause is unknown, factors such as genetic mutations, immune system dysfunction, chronic infections, and environmental exposures may contribute. Common signs and symptoms include painless swollen lymph nodes, fatigue, night sweats, unexplained weight loss, and frequent infections. Diagnosis involves physical examination, blood tests, imaging (CT, PET, or MRI scans), and most importantly, a lymph node or bone marrow biopsy confirmed through immunohistochemistry and flow cytometry, sometimes alongside genetic testing. Major subtypes of indolent lymphoma include follicular lymphoma (the most common), marginal zone lymphoma (including MALT lymphoma), and small lymphocytic lymphoma (SLL)/chronic lymphocytic lymphoma (CLL). Each has distinct characteristics but shares a generally slow progression, often managed with watchful waiting unless symptoms worsen or the disease transforms into a more aggressive form. Genetic and molecular testing may also be performed to determine the subtype and guide treatment decisions.

Indolent Lymphoma Treatment

Treatment for indolent lymphoma depends on the subtype, stage, symptoms, and overall health of the patient. Because it often progresses slowly, many patients with no or mild symptoms are managed with active surveillance (watchful waiting) until treatment becomes necessary. When intervention is required, options may include monoclonal antibody therapy (such as rituximab), chemotherapy, or immunochemotherapy combinations. Targeted therapies, including BTK inhibitors (e.g., zanubrutinib, ibrutinib) and PI3K inhibitors, are also used, especially in relapsed or refractory cases. Radioimmunotherapy and radiation therapy may be considered for localized disease, and in selected patients, stem cell transplantation could be an option after relapse. Newer treatments, such as CAR T-cell therapy and bispecific antibodies, are emerging in clinical trials, offering hope for more personalized and durable responses.

Indolent Lymphoma Epidemiology

The indolent lymphoma epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by the total incidence cases of indolent lymphoma, types-specific cases of indolent lymphoma, stage-specific cases of indolent lymphoma, and total treated cases of indolent lymphoma in the 7MM market covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

Indolent Lymphoma Drug Chapters

The drug chapter segment of the indolent lymphoma report encloses a detailed analysis of indolent lymphoma marketed and emerging pipeline drugs. It also deep dives into indolent lymphoma’s pivotal clinical trial details, recent and expected market approvals, patent details, the latest news, and recent deals and collaborations.

Currently, JAYPIRCA (pirtobrutinib), CALQUENCE (acalabrutinib), IMBRUVICA (Ibrutinib), BRUKINSA (zanubrutinib), EPKINLY (epcoritamab-bysp), ORDSPONO (odronextamab), KYMRIAH (tisagenlecleucel), YESCARTA (axicabtagene ciloleucel), and others are the FDA-approved drugs for treating indolent lymphoma. The drug chapter also helps understand the indolent lymphoma clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details, and the latest news and press releases.

Marketed Drugs

JAYPIRCA (pirtobrutinib): Eli Lilly

JAYPIRCA is a highly selective, non-covalent (reversible) inhibitor of Bruton's tyrosine kinase (BTK). BTK is a well-established therapeutic target in various B-cell malignancies, including mantle cell lymphoma, and chronic lymphocytic leukemia. JAYPIRCA is an FDA-approved oral treatment available in 100 mg and 50 mg tablets, taken once daily at a total dose of 200 mg, with or without food, and continued until disease progression or unacceptable toxicity occurs.

• In February 2025, Eli Lilly announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for JAYPIRCA (pirtobrutinib), for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia who have been previously treated with a BTK inhibitor.
• In December 2023, Eli Lilly announced the US Food and Drug Administration (FDA) approved JAYPIRCA (pirtobrutinib), 100 mg & 50 mg tablets for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

EPKINLY/ TEPKINLY (epcoritamab-bysp): AbbVie/Genmab

EPKINLY is a prescription medication used to treat adults with specific types of lymphoma, including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, and follicular lymphoma, that have returned or failed to respond after at least two prior treatments. Its approval is based on how patients responded during clinical trials, and additional studies are underway to confirm its overall clinical benefit. The safety and effectiveness of EPKINLY in children have not yet been established. Epcoritamab has received regulatory approval in certain lymphoma indications in several countries.

In June 2024,, AbbVie and Gnemab, announced US FDA has approved EPKINLY as the first and only T-cell engaging bispecific antibody administered subcutaneously for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma after two or more lines of prior therapy.

Emerging Therapies

AZD0486: AstraZeneca

AZD0486 (formerly TNB-486) is a novel, IgG4 fully human CD19xCD3 bispecific TCE incorporating a unique low-affinity anti-CD3 moiety designed to reduce cytokine release while retaining potent T-cell mediated cytotoxicity of malignant B cells. A silenced Fc prevents nonspecific binding and antibody-dependent cellular cytotoxicity and confers a long half-life suitable for intermittent administration.

In November 2024, At ASH 2024, AstraZeneca highlighted the strength of its hematology portfolio with two oral presentations on AZD0486, a novel CD19xCD3 bispecific T-cell engager. Phase I results show promising efficacy in patients with R/R follicular lymphoma, with a 96% ORR and 85% CRR at doses of 2.4 mg and above.

EO2463: Enterome

EO2463 is an innovative, off-the-shelf OncoMimics active immunotherapy that combines four synthetic peptides. These non-self, microbial-derived peptides correspond to CD8 HLA-A2 epitopes that exhibit molecular mimicry with the B lymphocyte-specific lineage markers CD20, CD22, CD37, and CD268 (BAFF receptor). It also includes the helper peptide (CD4+ epitope) universal cancer peptide 2 (UCP2).

In June 2025, Enterome presented positive interim results for its OncoMimic immunotherapy EO2463 from Cohorts 1 and 4 of the ongoing open label Phase I/II SIDNEY trial in patients with indolent non-Hodgkin lymphoma (iNHL), at the International Conference on Malignant Lymphoma (ICML) in Lugano.

Drug Class Insight

Bruton's tyrosine kinase inhibitor

BTK is a crucial enzyme in the B-cell receptor signaling pathway, playing a key role in the development, differentiation, and activation of B cells, which are vital components of the immune system. BTK transmits signals from the B-cell receptor to promote B-cell survival and proliferation. Dysregulation or overactivation of BTK is implicated in various B-cell malignancies, such as chronic lymphocytic leukemia, mantle cell lymphoma, and other non-Hodgkin lymphomas, making it an important therapeutic target. Inhibitors of BTK, such as ibrutinib and zanubrutinib, have been developed to block this pathway, thereby reducing malignant B-cell growth and survival.

Indolent Lymphoma Market Outlook

The treatment landscape for indolent lymphoma, a slow-growing subtype of non-Hodgkin lymphoma, has evolved significantly, offering a range of options tailored to disease stage, symptoms, and patient health. In early-stage or asymptomatic cases, a “watch and wait” approach is often preferred, as immediate treatment may not improve outcomes. When intervention is needed, monoclonal antibodies are frontline agents, commonly used alone or in combination with chemotherapy regimens like bendamustine, CHOP, or CVP. For patients with relapsed or refractory disease, targeted therapies play a key role these include BTK inhibitors (e.g., ibrutinib, zanubrutinib), PI3K inhibitors (e.g., copanlisib, duvelisib, umbralisib), and EZH2 inhibitors such as tazemetostat, particularly in EZH2-mutated follicular lymphoma. In more advanced settings, CAR T-cell therapies (e.g., axi-cel, liso-cel) and bispecific antibodies like epcoritamab and mosunetuzumab are showing high response rates in clinical trials and real-world use. Additional strategies such as radioimmunotherapy and autologous stem cell transplant may be considered for select patients. Ongoing research into immunotherapies and personalized medicine continues to expand treatment possibilities, aiming for deeper, more durable remissions with fewer side effects.

Indolent Lymphoma Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2025-2034. The landscape of indolent lymphoma treatment has experienced a profound transformation with the uptake of novel medicines. These innovative therapies are redefining standards of care.

Indolent Lymphoma Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I/II stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions and mergers, licensing, and patent details for indolent lymphoma emerging therapies.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Some of the leaders like MD, Professors, Directors, PhD, and others. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or indolent lymphoma market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

The analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the University of Florida, Virginia Commonwealth University etc. were contacted. Their opinion helps understand and validate indolent lymphoma epidemiology and market trends.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of gaps in disease diagnosis, patient awareness, physician acceptability, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint Analysis analyzes multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

In efficacy, the trial’s primary and secondary outcome measures are evaluated; for instance, in event-free survival, one of the most important primary outcome measures is event-free survival and overall survival.

Further, the therapies’ safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and a payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health technology assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug. In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs, including Medicare, Medicaid, Health Insurance Program (CHIP), and the state and federal health insurance marketplaces, are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs) and third-party organizations that provide services and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of currently used therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Report

• The report covers a descriptive overview of Indolent Lymphoma, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight has been provided into Indolent Lymphoma epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Indolent Lymphoma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the Indolent Lymphoma market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Indolent Lymphoma market.

Indolent Lymphoma Report Insights

Indolent Lymphoma Report Insights

• Patient Population
• Therapeutic Approaches
• Indolent Lymphoma Pipeline Analysis
• Indolent Lymphoma Market Size and Trends
• Market Opportunities
• Impact of Upcoming Therapies

Indolent Lymphoma Report Key Strengths

• Ten Years Forecast
• 7MM Coverage
• Indolent Lymphoma Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Indolent Lymphoma Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs

• What was the indolent lymphoma market share (%) distribution in 2024 and what it would look like in 2034?
• What would be the indolent lymphoma total market size as well as market size by therapies across the 7MM during the study period (2020-2034)?
• What are the key findings about the market across the 7MM and which country will have the largest indolent lymphoma market size during the study period (2020-2034)?
• What would be the indolent lymphoma market growth till 2034?
• What are the disease risks, burdens, and unmet needs of indolent lymphoma?
• What is the historical indolent lymphoma patient pool in the United States, EU4 (Germany, France, Italy, and Spain), and the UK, and Japan?
• What will be the growth opportunities across the 7MM concerning the patient population of indolent lymphoma?
• At what CAGR the population is expected to grow across the 7MM during the study period (2020-2034)?
• How many emerging therapies are in the mid-stage and late stage of development for the treatment of indolent lymphoma?
• What are the key collaborations (industry-industry, industry-academia), mergers and acquisitions, and licensing activities related to indolent lymphoma therapies?
• What are the key designations that have been granted for the emerging therapies for indolent lymphoma?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the indolent lymphoma market.
• To understand the future market competition in the indolent lymphoma market and insightful review of the SWOT analysis of indolent lymphoma.
• Organize sales and marketing efforts by identifying the best opportunities for indolent lymphoma in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the indolent lymphoma market.
• To understand the future market competition in indolent lymphoma.

This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.